|Bid||0.00 x 1100|
|Ask||0.00 x 1800|
|Day's Range||11.79 - 12.39|
|52 Week Range||6.81 - 23.77|
|Beta (3Y Monthly)||0.07|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 30, 2019 - Nov 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.11|
WALTHAM, Mass., Sept. 12, 2019 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) (“AMAG” or the “Company”) today issued the following letter, which will be mailed to its.
AMAG Pharmaceuticals (AMAG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The New York firm hopes to replace four of the nine members of Amag’s board with, among others, the former CEO of actress Gwyneth Paltrow’s wellness and lifestyle company Goop, Lisa Gersh.
“AMAG regularly engages with shareholders on a range of topics and values their constructive input and is committed to act in the best interest of shareholders to maximize long-term value creation. “AMAG remains open to maintaining a constructive dialogue with Caligan, as it does with all shareholders, about AMAG’s strategy to create sustainable, long-term value. However, the Company remains steadfast in its belief that any corporate action taken must be for the benefit of all Company shareholders and must be rooted in a strong understanding of the pharmaceutical industry, AMAG’s business and its important milestones ahead.
(Bloomberg) -- Shares in Amag Pharmaceuticals Inc. jumped after activist investor Caligan Partners said it planned to ask shareholders to replace four of the company’s directors, including Chairman Gino Santini.Caligan owns about 10.3% of the pharmaceutical company, which is launching the female libido drug Vyleesi. The New York-based hedge fund has been pushing for changes at Amag Pharma, including calling for a strategic review, cost cuts and the international expansion of its Feraheme kidney drug, according to a statement Wednesday, confirming an earlier report by Bloomberg.Shares in Amag Pharma rose 6.4% in trading Wednesday in New York to $11.96 at 9:36 a.m., giving the company a market valuation of $406 million.“We believe urgent change is needed at AMAG to reverse the sharp share price decline caused by the company’s misguided strategic priorities,” David Johnson, co-founder and managing partner at Caligan, in the statement.A representative for Amag Pharma, which is based in Waltham, Massachusetts, wasn’t immediately available for comment.Caligan, which Johnson co-founded with former Carl Icahn associate Sam Merksamer, believes Amag Pharma is undervalued and its portfolio of assets could be worth at least $30 a share, according to a presentation posted on a website dedicated to Caligan’s campaign at the company. The investment firm argues that the company’s shares have tumbled despite almost $1.4 billion spent on non-Feraheme research and development since 2012, the presentation states.Its shared had fallen 26% year to date through Tuesday’s close.Caligan is calling for a strategic review of its businesses that could result in splitting up the company, selling rights to some products or exploring partnerships, including for its women’s health segment, according to people familiar with the matter. It also contends the company’s spending is out of line with its peers, the people said, asking not to be identified because the matter is not public.Amag Pharma’s bylaws don’t allow shareholders to call a special meeting to vote for Caligan’s nominees. Instead, the hedge fund is seeking written consent from more than 50% of Amag Pharma shareholders to replace the four directors, the firm said.Caligan’s nominees are: former Boehringer Ingelheim USA Corp. Chief Executive Officer Paul Fonteyne; Alexander Wang Inc.’s ex-CEO, Lisa Gersh; Caligan’s David Johnson; and Kenneth Shea, a Guggenheim Securities LLC senior adviser. The investment firm is putting forth Fonteyne as a potential candidate for chairman, the people said.(Updates with Caligan statement starting in first paragraph; share price in paragraph three.)To contact the reporter on this story: Scott Deveau in New York at email@example.comTo contact the editors responsible for this story: Liana Baker at firstname.lastname@example.org, Ben Scent, Amy ThomsonFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
AMAG Pharmaceuticals, Inc. (AMAG) announced today that Vyleesi™ (bremelanotide injection), a melanocortin receptor agonist indicated for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, is now commercially available through specialty pharmacies, Avella and BioPlus. Once prescribed, Vyleesi is delivered directly to a woman’s home. "In my practice I see many women who suffer from HSDD, a medical condition which impacts approximately 1 in 10 U.S. women," said Brooke Faught, DNP, WHNP-BC, NCMP, IF, Director of the Women’s Institute for Sexual Health.
AMAG Pharmaceuticals, Inc. (AMAG) today announced that the Board of Directors of AMAG approved inducement awards to a new employee of (i) an option to purchase 16,700 shares of common stock and (ii) 8,500, restricted stock units. The option will have an exercise price equal to the closing price of AMAG’s common stock on the grant date and will be exercisable in four equal annual installments beginning on the first anniversary of August 19, 2019 (the grant date).
"If the products that the (FDA) is approving aren't standing the test of time, are they going to become more tentative with drug approvals? (Cell and gene therapies) may bring that issue to the forefront," one regulatory expert said.
A New York investment firm disclosed a 10.3% stake in Amag Pharmaceuticals and said it would consider proposing a number of changes at the Waltham, Mass., drugmaker. Other proposals to Amag might include changes to its operations, management, board, dividend policy and strategy, among other things, the filing says.
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
On CNBC's "Mad Money Lightning Round," Jim Cramer said he doesn't like the airlines right now. It's not the right place to be. He would take a look at Delta Air Lines, Inc. (NYSE: DAL ) when ...
AMAG Pharmaceuticals, Inc. (AMAG) today announced that the Board of Directors of AMAG approved inducement awards to a new employee of (i) an option to purchase 14,500 shares of common stock and (ii) 7,500 restricted stock units. The option will have an exercise price equal to the closing price of AMAG’s common stock on the grant date and will be exercisable in four equal annual installments beginning on the first anniversary of August 12, 2019 (the grant date).
AMAG Pharmaceuticals (AMAG) reports wider-than-expected loss and sales miss in the second quarter of 2019. The company lowers its 2019 view.
AMAG Pharmaceuticals (AMAG) delivered earnings and revenue surprises of -93.94% and -15.17%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Promoted products achieved sequential and year-over-year revenue and market share growth 2019 financial guidance lowered: exiting Makena.
Amag Pharmaceuticals Inc's treatment to boost sexual desire in premenopausal women will be offered at $899 and is the only injectable drug on the market for hypoactive sexual desire disorder (HSDD). It will compete with Sprout Pharmaceuticals' Addyi, a once-daily pill. "It's not a one size fits all solution ... There is no ideal desire," Dr. Julie Krop, Amag's chief medical officer, told Reuters.
It will compete with Sprout Pharmaceuticals' Addyi, a once-daily pill. "It's not a one size fits all solution ... There is no ideal desire," Dr. Julie Krop, Amag's chief medical officer, told Reuters.
AMAG Pharmaceuticals (AMAG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WALTHAM, Mass., July 29, 2019 -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that its second quarter 2019 financial results will be released on Wednesday, August.